Payment overview · 2025
General Payments
$1,938.12
64 reported records · 18 companies
Healthcare provider profile · identity verified
Christopher G Carsten, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · GREENVILLE, SC · NPI 1275586471
Verified facts
What the public records show
CMS Open Payments records show Christopher G Carsten, M.D. received $1,938.12 in general payments during 2025 across 64 reported records.
Cook Medical LLC accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cook Medical LLC | Unresolved — no canonical attribution shown | $419.55 | 21.6% | 12 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $380.08 | 19.6% | 13 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $233.54 | 12.1% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$204.99 | 10.6% | 8 | 2025 |
| RedDress USA, Inc. | Unresolved — no canonical attribution shown | $143.62 | 7.4% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $137.99 | 7.1% | 2 | 2025 |
| VentureMed Group, Inc. | Unresolved — no canonical attribution shown | $61.04 | 3.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $57.52 | 3.0% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $56.67 | 2.9% | 3 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $42.90 | 2.2% | 2 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $40.00 | 2.1% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $34.92 | 1.8% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $32.70 | 1.7% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $30.67 | 1.6% | 2 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $17.05 | 0.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.92 | 0.8% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $15.20 | 0.8% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $13.76 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,938.12 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $264.21 | 12 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $264.21 | 12 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $239.67 | 7 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $188.99 | 4 | 2025 |
Source payment records
|
|||||
| ActiGraft Normalized: actigraft |
Device | RedDress USA, Inc. | $143.62 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $142.42 | 3 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $138.41 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $137.99 | 2 | 2025 |
Source payment records
|
|||||
| FLEX Vessel Prep System Normalized: flex vessel prep system |
Device | VentureMed Group, Inc. | $61.04 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Stent Graft Normalized: gore tag conformable thoracic stent graft |
Device | W. L. Gore & Associates, Inc. | $43.68 | 1 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $42.90 | 2 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $40.00 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| FORTREX Normalized: fortrex |
Device | Medtronic, Inc. | $36.74 | 3 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| COOK CELECT Normalized: cook celect |
Device | Cook Medical LLC | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $34.92 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $32.70 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIATORR TIPS Endoprosthesis with Controlled Expansion Normalized: gore viatorr tips endoprosthesis with controlled expansion |
Device | W. L. Gore & Associates, Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| EVERCROSS Normalized: evercross |
Device | Medtronic, Inc. | $17.71 | 2 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| ADVANCE Normalized: advance |
Device | Cook Medical LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $6.36 | 1 | 2025 |
Source payment records
|
|||||
| MVP Normalized: mvp |
Device | Medtronic, Inc. | $5.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,938.12 · 64 records | Cook Medical LLC | ADVANCE, AZUR CX DETACHABLE, ActiGraft, CGuard Prime Carotid Stent System, COLLAGENASE SANTYL, COOK, COOK CELECT, CT THROMBECTOMY SYSTEM KIT, ELUVIA, ENDURANT IIS, EVERCROSS, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLEX Vessel Prep System, FLOWTRIEVER CATHETER, S, FORTREX, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Conformable Thoracic Stent Graft, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, GORE VIATORR TIPS Endoprosthesis with Controlled Expansion, General - Therapies, IMPEDE EMBOLIZATION PLUG, IN.PACT AV, Indigo System, MVP, Miro3D, NAVICROSS, Penumbra System, ROSEN, Restrata Wound Matrix, SYMPHONY CATHETER, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, ZILVER PTX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error